Notícias

They have a combined 181 years of consecutive payout increases.

Price targets on Johnson & Johnson have been moving higher, with bullish analysts now citing a range from about US$260 to US$305. This shift is closely linked to recent Street commentary that highlights solid execution in new medicines and MedTech, along with reduced legal uncertainty around talc litigation. As you read on, you will see how these changing targets fit into the broader analyst narrative and what to watch to stay on top of the story. Stay updated as the Fair Value for Johnson &...

Johnson & Johnson (JNJ) just issued one of the weirdest profit warnings in health care. The biotech business decreased its 2026 adjusted earnings guidance to between $10.96 and $11.11 a share, from a range of $11.60 to $11.75. This year, the newly closed acquisition of Firefly Bio and the ...

Abbott trades at a cheaper valuation but carries higher litigation risk, while J&J boasts superior profitability despite a pending talc settlement.

Johnson & Johnson (NYSE:JNJ) delivered strong fiscal Q2 2026 results, with sales for the quarter growing nearly 7% to $25.31 ⁠billion, above analysts’ average estimate of about $25.05 billion. Adjusted earnings per share reached $2.90, surpassing the expectation of $2.85. The company also raised its guidance and stated that it is on track to meet […]

LQDA heads into its Q2 earnings with Yutrepia driving growth, rising profitability and a self-funded pipeline as investors watch quarterly performance.

AbbVie tops Q2 earnings and revenue estimates on strong immunology drug sales, but a lower 2026 EPS outlook tied to the Apogee deal weighs on shares.

AbbVie (ABBV) lowered its full-year earnings guidance on Friday to account for the expected dilution

Eli Lilly stock ran on a story that was public and dated long before the price moved, and reading it right still would not have put you ahead of every peer.

Here is a way to get paid a meaningful income now on your Eli Lilly shares, income you keep no matter what the stock does, in exchange for agreeing to sell at a price above today's if it climbs there.

Johnson & Johnson has rallied the broader market over the past year, and analysts remain moderately bullish about the stock’s prospects.

J&J strikes this deal with Sail as the in vivo CAR-T space becomes increasingly crowded.

The project, which is largely tied to the innovative medicine segment, will see the company exit certain facilities and incur costs of up to $750 million.

Things are going well for the pharmaceutical giant.

Healthcare stocks declined late Thursday afternoon, with the NYSE Healthcare Index shedding 1.5% and

Healthcare stocks declined Thursday afternoon, with the NYSE Healthcare Index falling 1.7% and the S

MRK heads into Q2 earnings with acquisition costs, Keytruda strength and Gardasil challenges likely to shape results. Is the stock still worth holding?

Wall Street is set to open higher on Thursday as strong Microsoft results helped technology stocks recover from their sharp post-Federal Reserve sell-off. Dow Jones futures were up 225 points, or 0.4%, while S&P 500 futures pointed to a 0.6% gain and the Nasdaq was called 1.3%...

The deal with the buzzy Flagship Pioneering-backed startup makes J&J the latest large drugmaker to bet that the technology might be able to treat autoimmune conditions.

Bristol Myers Squibb faces declining revenue in its legacy drug portfolio, but new products like Opdivo are offsetting the drop.

Johnson & Johnson proposed a $5.5b settlement to resolve tens of thousands of ovarian cancer talc lawsuits. The offer aims to address a decade-long legal dispute involving the company’s talcum powder products. The settlement would require approval from a majority of claimants before it can move forward. For investors watching Johnson & Johnson (NYSE:JNJ), this legal development sits alongside a stock that closed at $265.53 and has recently shown strong momentum. The shares are up 3.9% over...

Under the agreement, Johnson & Johnson would make total initial payments of $785 million, and has the exclusive option to acquire Sail for $2.58 billion.

But is that performance sustainable?

Moby summary of Anika Therapeutics, Inc.'s Q2 2026 earnings call

Eighteen thousand dollars a month is the number a lot of high earners target for retirement: it replaces a $216,000 salary, covers property taxes in a coastal state, and funds the lifestyle most doctors, senior engineers, and business owners built around. On a $3 million portfolio, hitting that figure requires a blended yield of roughly ... This $3 Million Portfolio Pays $18,000 a Month From Three Income Buckets

The sticker shock on the pharma giant's shares fades once you look at what investors are paying for the earnings expected just two years from now.

GSK beats Q2 earnings and revenue estimates, reaffirms 2026 guidance and unveils a new cost-saving plan.

Boston Scientific (BSX) lowered its full-year guidance below Wall Street's estimates on Wednesday, c

Host Kenny Polcari, Robinhood CIO Stephanie Guild, and Payne Capital Management President Ryan Payne discuss why they believe the AI trade is still alive, and how investors can reduce spending risk by looking beyond hyperscalers and semiconductors.

In the world of robotic surgery, one company is both the undisputed leader and the most expensive name on the shelf, forcing investors to ask if operational brilliance is worth the high price of admission.